PT-141: Dosage, Benefits & Side Effects
By Peptide Assistant Editorial Team · · · 12 sources cited
Overview
PT-141 (bremelanotide) is a synthetic melanocortin peptide and the only FDA-approved on-demand treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women, marketed as Vyleesi. Originally derived from Melanotan-2 during clinical development, PT-141 is a centrally-acting sexual dysfunction drug — it works in the brain rather than on peripheral blood flow, making it effective for desire-based dysfunction rather than purely mechanical arousal problems. It is thought to act through melanocortin-4 receptors (MC4R) in the hypothalamus to increase sexual desire; the FDA label states that its exact mechanism in women is unknown and that it is not indicated for men.
Mechanism of Action
PT-141 is a cyclic heptapeptide (Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-OH) structurally derived from Melanotan-2 and, like it, active at several melanocortin receptors, including MC1R (pigmentation) and MC4R (sexual effects). Its mechanism of action is centrally mediated and fundamentally different from PDE5 inhibitors (Viagra, Cialis) or hormonal approaches. PT-141 is a nonselective melanocortin agonist, and animal studies suggest it acts on MC4R in the medial preoptic area (MPOA) and paraventricular nucleus (PVN) of the hypothalamus — brain regions that serve as integration centers for sexual motivation, arousal, and autonomic genital response. MC4R activation in the PVN triggers descending oxytocin and dopaminergic pathways that increase sexual desire at the motivational level while simultaneously activating autonomic pathways to the sacral spinal cord that mediate genital arousal responses. In males, this descending pathway activates parasympathetic neurons in the sacral erection center (S2–S4), producing penile erection through a mechanism entirely independent of the NO/cGMP/PDE5 cascade targeted by sildenafil. This means PT-141 can produce erections in men who do not respond to PDE5 inhibitors, particularly those with psychogenic erectile dysfunction or mixed-etiology ED where desire is a significant component. In females, the same hypothalamic pathways are thought to raise subjective sexual desire; in a small crossover study women reported more desire after bremelanotide, while measured vaginal blood flow did not change significantly. The distinction is critical: PT-141 increases wanting (desire/motivation) rather than merely enabling physical arousal — it addresses the psychological and neurological roots of sexual dysfunction. PT-141 also modulates dopamine release in the mesolimbic reward pathway, contributing to increased anticipatory pleasure and sexual motivation. PT-141 is not receptor-selective: the Vyleesi label ranks its potency as MC1R, MC4R, MC3R, MC5R, then MC2R, and its MC1R activity can darken skin (focal hyperpigmentation), especially with daily dosing. The peptide has a half-life of approximately 2.7 hours after subcutaneous injection, with peak blood levels about 1 hour post-dose. The FDA label states that the duration of effect after each dose is unknown.
PT-141 Benefits: What the Research Shows
- The RECONNECT Phase III trials (n=1,247 premenopausal women) demonstrated bremelanotide significantly increased sexual desire and reduced distress associated with low sexual desire compared to placebo, leading to FDA approval in 2019
- Rosen et al. (2004) in the International Journal of Impotence Research showed subcutaneous PT-141 (4 or 6 mg) produced a statistically significant erectile response versus placebo in men with erectile dysfunction who had an inadequate response to sildenafil
- Pfaus et al. (2004) published foundational research in PNAS showing PT-141 selectively increased solicitation behaviors in female rats without affecting lordosis, pointing to central melanocortin systems in the regulation of female sexual desire
- Clayton et al. (2016) in Women's Health reported a phase 2b dose-finding trial (n=327) in which subcutaneous bremelanotide 1.25 and 1.75 mg increased satisfying sexual events and improved sexual function and distress scores versus placebo, setting the dose for the pivotal trials
- Wessells et al. (2003) showed in rats that Melanotan-2, the parent peptide of PT-141, induced erections through melanocortin receptors in the brain and spinal cord and not through a direct action in the penis, supporting a central mechanism
- A 2004 study in the International Journal of Impotence Research showed PT-141 nasal spray produced a significant erectile response at doses above 7 mg in healthy men and men with erectile dysfunction; the intranasal route was later dropped in favor of subcutaneous injection because of variable absorption and blood pressure increases
PT-141 Dosage
- FDA-approved dose (Vyleesi): 1.75 mg subcutaneous injection in the abdomen or thigh, at least 45 minutes before anticipated sexual activity
- Maximum frequency: once per 24 hours; no more than 8 doses per month per FDA labeling
- Off-label male dosing: 1.0–2.0 mg subcutaneous injection 1–3 hours before sexual activity
- Some male protocols use lower doses of 0.5–1.0 mg to reduce side effects while maintaining efficacy
- Start with the lowest effective dose — many users find 1.0 mg sufficient, and side effects are dose-dependent
- Do not pre-treat with antiemetics containing dopamine antagonists, as they may reduce PT-141's pro-sexual effects
- For nausea management: start with 0.5 mg to assess tolerance; nausea typically diminishes with subsequent doses
- Not intended for daily use — on-demand dosing preserves efficacy and minimizes side effects
- Effects onset: 45 minutes to 2 hours; peak effects at 1–3 hours post-injection
- Avoid concurrent use with PDE5 inhibitors unless under medical supervision (theoretical risk of additive blood pressure effects)
Disclaimer: Dosing information is compiled from research literature and community protocols for educational purposes only. This is not medical advice. Always consult a qualified healthcare provider before starting any peptide protocol.
PT-141 Side Effects & Safety
Known Side Effects
- Nausea — the most common side effect, occurring in approximately 40% of users in clinical trials; usually mild-moderate and peaks 1–2 hours post-injection; diminishes significantly with repeated use
- Facial flushing — warmth and redness lasting 30–90 minutes, reported in approximately 20% of users
- Injection site reactions — pain, redness, or bruising at the subcutaneous injection site
- Headache — reported in approximately 10% of clinical trial participants
- Transient blood pressure elevation — the intranasal formulation was abandoned due to this concern; the subcutaneous route has a more favorable hemodynamic profile, but blood pressure should be monitored in hypertensive individuals
- Skin hyperpigmentation — darkening of the face, gums or breasts was reported in 1% of patients using up to 8 doses per month and in 38% after 8 days of daily dosing, and it did not always fade after stopping; the FDA label recommends limiting to 8 doses per month partly for this reason
- Fatigue or drowsiness — reported by some users after the sexual effects subside
- Priapism — theoretically possible given the erectogenic mechanism, though no cases were reported in clinical trials at approved doses
Safety Profile
PT-141 (bremelanotide) has a well-characterized safety profile from extensive Phase I–III clinical trials and post-marketing surveillance following its 2019 FDA approval. The RECONNECT trials enrolled over 1,200 women with a favorable safety profile. The most significant safety consideration is transient blood pressure elevation — the earlier intranasal formulation was associated with clinically significant BP increases, leading to reformulation as a subcutaneous injection with a better hemodynamic profile. Nevertheless, PT-141 is contraindicated in patients with uncontrolled hypertension or known cardiovascular disease. The FDA labeling limits use to 8 doses per month to minimize the risk of hyperpigmentation with repeated MC1R exposure. There is no evidence of physical dependence, tolerance, or withdrawal. Drug interactions include oral naltrexone (bremelanotide can substantially lower naltrexone blood levels, so the label says to avoid it in people taking naltrexone for alcohol or opioid addiction) and PDE5 inhibitors (potential additive hypotension). Mild to moderate hepatic or renal impairment does not require dose adjustment; the label advises caution in severe hepatic or renal impairment, where side effects such as nausea may be more frequent or severe.
What to Expect
45 minutes–2 hours post-injection: Nausea and flushing are most common in this window, particularly with the first 1–3 uses. Nausea is usually mild and passes within 1–2 hours. Alongside the side effects, a growing sense of sexual desire and awareness begins. 2–4 hours: Peak sexual effects. Users describe a distinctly increased desire for intimacy — not a forced arousal but a natural amplification of sexual interest and responsiveness. Physical arousal responses are heightened: men report firmer erections with less mental effort, women report increased genital sensation, lubrication, and desire. Unlike PDE5 inhibitors, the effect feels motivational rather than mechanical. 4–12 hours: Sexual enhancement gradually diminishes but remains noticeable. Some users report a lingering 'afterglow' of increased desire and sensitivity for up to 24 hours. Subsequent uses: Nausea typically decreases significantly after the first 2–3 doses while sexual effects remain consistent. Most users find their optimal dose within 2–3 uses. Long-term: No tolerance development has been observed with on-demand use (limited to 8 times per month). Effects remain consistent over months of intermittent use.
Common Stacks
Melanotan 2
Some users who want both tanning and sexual enhancement use MT-2 for tanning cycles and PT-141 for on-demand sexual enhancement, leveraging each compound's strength
Oxytocin
Oxytocin enhances emotional bonding and intimacy while PT-141 addresses the physical desire and arousal component — complementary aspects of sexual experience
Kisspeptin-10
Kisspeptin-10 activates GnRH and reproductive hormone signaling upstream of the melanocortin pathway, potentially complementing PT-141's central arousal effects
Storage & Handling
Store lyophilized PT-141 at 2–8°C (refrigerated) for up to 12 months, or at -20°C for longer-term storage. Reconstitute with bacteriostatic water — typically 1 mL per 10 mg vial. After reconstitution, store refrigerated at 2–8°C and use within 4–6 weeks. The FDA-approved Vyleesi product comes as a single-dose prefilled autoinjector stored at or below 25°C (do not freeze), with a shelf life indicated on the packaging. Protect from light. Discard any unused reconstituted solution after 6 weeks.
Pricing & Available Variants
Prices sourced from peptides.gg marketplace. Prices may vary.
References
- Vyleesi (bremelanotide injection), for subcutaneous use: prescribing information. Cosette Pharmaceuticals, via DailyMed. 2026.
- Kingsberg SA, Clayton AH, Portman D, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol. 2019.
- Simon JA, Kingsberg SA, Portman D, et al. Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder. Obstet Gynecol. 2019.
- Clayton AH, Kingsberg SA, Portman D, et al. Safety Profile of Bremelanotide Across the Clinical Development Program. J Womens Health (Larchmt). 2022.
- Clayton AH, Althof SE, Kingsberg S, et al. Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial. Womens Health (Lond). 2016.
- White WB, Myers MG, Jordan R, et al. Usefulness of ambulatory blood pressure monitoring to assess the melanocortin receptor agonist bremelanotide. J Hypertens. 2017.
- Rosen RC, Diamond LE, Earle DC, et al. Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra. Int J Impot Res. 2004.
- Diamond LE, Earle DC, Rosen RC, et al. Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. Int J Impot Res. 2004.
- Diamond LE, Earle DC, Heiman JR, et al. An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist. J Sex Med. 2006.
- Pfaus JG, Shadiack A, Van Soest T, et al. Selective facilitation of sexual solicitation in the female rat by a melanocortin receptor agonist. Proc Natl Acad Sci U S A. 2004.
- Wessells H, Hruby VJ, Hackett J, et al. Ac-Nle-c[Asp-His-DPhe-Arg-Trp-Lys]-NH2 induces penile erection via brain and spinal melanocortin receptors. Neuroscience. 2003.
- Pfaus JG, Sadiq A, Spana C, et al. The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women. CNS Spectr. 2022.
Related Peptides
Track PT-141 in Your Protocol
Log your PT-141 doses, track consistency, and monitor your protocol with Peptide Assistant — completely free.
Start Tracking Free